Lyman GH - Search Results

1

Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.

Weycker D, Li X, Tzivelekis S, Atwood M, Garcia J, Li Y, Reiner M, Lyman GH. Weycker D, et al. Among authors: lyman gh. Support Care Cancer. 2017 Feb;25(2):439-447. doi: 10.1007/s00520-016-3421-x. Epub 2016 Oct 12. Support Care Cancer. 2017. PMID: 27734153

2

The economics of febrile neutropenia: implications for the use of colony-stimulating factors.

Lyman GH, Kuderer N, Greene J, Balducci L. Lyman GH, et al. Eur J Cancer. 1998 Nov;34(12):1857-64. doi: 10.1016/s0959-8049(98)00222-6. Eur J Cancer. 1998. PMID: 10023306

3

Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis.

Lyman GH, Kuderer NM, Djulbegovic B. Lyman GH, et al. Am J Med. 2002 Apr 1;112(5):406-11. doi: 10.1016/s0002-9343(02)01036-7. Am J Med. 2002. PMID: 11904116

4

Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.

Lyman GH, Delgado DJ. Lyman GH, et al. Cancer. 2003 Dec 1;98(11):2402-9. doi: 10.1002/cncr.11827. Cancer. 2003. PMID: 14635075 Free article.

5

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.

Crawford J, Dale DC, Lyman GH. Crawford J, et al. Among authors: lyman gh. Cancer. 2004 Jan 15;100(2):228-37. doi: 10.1002/cncr.11882. Cancer. 2004. PMID: 14716755 Free article. Review.

6

The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.

Lyman GH, Kuderer NM. Lyman GH, et al. Crit Rev Oncol Hematol. 2004 May;50(2):129-46. doi: 10.1016/j.critrevonc.2004.01.001. Crit Rev Oncol Hematol. 2004. PMID: 15157662 Review.

7

The colony-stimulating factors: use to prevent and treat neutropenia and its complications.

Komrokji RS, Lyman GH. Komrokji RS, et al. Among authors: lyman gh. Expert Opin Biol Ther. 2004 Dec;4(12):1897-910. doi: 10.1517/14712598.4.12.1897. Expert Opin Biol Ther. 2004. PMID: 15571452 Review.

8

Risk models for predicting chemotherapy-induced neutropenia.

Lyman GH, Lyman CH, Agboola O. Lyman GH, et al. Among authors: lyman ch. Oncologist. 2005 Jun-Jul;10(6):427-37. doi: 10.1634/theoncologist.10-6-427. Oncologist. 2005. PMID: 15967836 Free article. Review.

9

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Kuderer NM, et al. Among authors: lyman gh. Cancer. 2006 May 15;106(10):2258-66. doi: 10.1002/cncr.21847. Cancer. 2006. PMID: 16575919 Free article.

10

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.

Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C; European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party. Aapro MS, et al. Among authors: lyman gh. Eur J Cancer. 2006 Oct;42(15):2433-53. doi: 10.1016/j.ejca.2006.05.002. Epub 2006 Jun 5. Eur J Cancer. 2006. PMID: 16750358 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

572 results

Search Page

Filters